Nasus Pharma Ltd (NSRX) shareholders
Close on Nov 17, 2026Market cap $23.53MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Udi Gilboa | 1,901,311 | 21.10% | 13G (passive) | Sep 30, 2025 |
| Dr. Dalia Megiddo | 1,888,873 | 20.90% | 13G (passive) | Sep 30, 2025 |
| Dr. Ronnie Hershman Joint filing with Hershman Holdings LLC (9.90%) | 1,383,512 | 15.30% | 13G (passive) | Sep 30, 2025 |
| Dames GP LLC Joint filing with Balyasny Asset Management L.P. (9.99%), Bam Gp LLC (9.99%) and 2 more | 1,169,910 | 9.99% | 13G (passive) | Mar 31, 2026 |
| Balyasny Asset Management L.P. Joint filing with Bam Gp LLC (9.99%), Balyasny Asset Management Holdings LP (9.99%) and 2 more | 1,169,909 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Ma-Weaver Jacob Joint filing with Funicular Funds, LP (5.20%), Cable Car Capital, LP (5.20%) | 612,913 | 5.20% | 13G (passive) | Mar 31, 2026 |
| Capital Point Ltd. | 575,129 | 6.35% | 13G (passive) | Aug 14, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NSRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Balyasny Asset Management L.P. | 898,473 | 9.97% | $3.14M | – | 0.00% |
| Cable Car Capital, LP | 616,081 | 6.83% | $2.16M | +14,083 | 0.05% |
| Velan Capital Investment Management LP | 359,390 | 3.99% | $1.26M | – | 0.77% |
| Hudson Bay Capital Management LP | 134,771 | 1.49% | $471.70K | – | 0.00% |
| Bleichroeder LP | 89,848 | 1.00% | $314.47K | – | 0.06% |
| Citadel Advisors LLC | 22,004 | 0.24% | $77.01K | New | 0.00% |
| XTX Topco Ltd | 16,640 | 0.18% | $58.24K | New | 0.00% |
| Renaissance Technologies LLC | 12,200 | 0.14% | $42.70K | New | 0.00% |
| Morgan Stanley | 1,000 | 0.01% | $3.50K | −1,000 | 0.00% |
| Caitong International Asset Management Co., Ltd | 4 | 0.00% | $14 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10 | 2M | 23.9% | 4 / 1 | 1 / 3 | 0M | 0M |
| Q1 2026 | 9 | 2M | 24.1% | 7 / 1 | 0 / 0 | 2M | 0M |
| Q4 2025 | 2 | 0M | 0.0% | 0 / 0 | 1 / 0 | 0M | 0M |
| Q3 2025 | 2 | 0M | 0.0% | 2 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Brendan P. O'Grady | Chief Executive Officer, Director | – | – | Nov 13, 2026 |
| Dan Benjamin Teleman | Chief Executive Officer, Director | 163,541 | 1.81% | Jul 29, 2026 |
| Dalia Megiddo | Chief Development Officer, Director | 1,894,068 | 21.01% | Mar 27, 2026 |
| Oren Elmaliah | Interim CFO | – | – | Nov 16, 2026 |
| Eyal Rubin | Chief Financial Officer | – | – | Sep 21, 2026 |
| Sharon Shacham | Director | – | – | Mar 27, 2026 |
| David Silberman | Director | – | – | Mar 27, 2026 |
| Isaac Israel | Director | – | – | Mar 27, 2026 |
| Ronnie Hershman | Director | 1,338,463 | 14.85% | Mar 27, 2026 |
| Udi Gilboa | – | 1,924,476 | 21.35% | Mar 27, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dan Benjamin Teleman Chief Executive Officer, Director | Jun 17, 2026 | Buy | +6,550 | $3.10 | $20.31K | 163,541 |
| Dan Benjamin Teleman Chief Executive Officer, Director | Apr 22, 2026 | Buy | +2,900 | $3.76 | $10.90K | 156,991 |
| Dan Benjamin Teleman Chief Executive Officer, Director | Mar 31, 2026 | Buy | +15,000 | $2.04 | $30.60K | 21,246 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Nasus Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 4,351 shares on Oct 5, 2026 over the last 90 days.
See a number that looks wrong?